2-氟丙二酸二甲酯 | 344-14-9

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氟丙二酸二甲酯
• 中文别名: 氟丙二酸二甲酯；二甲基氟丙二酸酯；2-氟-4-甲氧基乙酰乙酸甲酯；2-氟代丙二酸二甲酯
• 英文名称: dimethyl 2-fluoromalonate
• 英文别名: dimethyl fluoromalonate；dimethyl fluoropropanedioate；dimethyl 2-fluoropropanedioate；dimethyl α-fluoromalonate；2-fluoromalonic acid dimethyl ester
• CAS: 344-14-9
• 化学式: C₅H₇FO₄
• mdl: MFCD00054680
• 分子量: 150.107
• InChiKey: ZVXHZSXYHFBIEW-UHFFFAOYSA-N

物化性质

• 沸点：
  76 °C
• 密度：
  1.4g/ml
• 闪点：
  111-112°C/45mm

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险等级：
  8
• 危险品标志：
  T,C
• 安全说明：
  S23,S23 2636/37/3945,S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2917190090
• 危险品运输编号：
  3265
• 危险类别：
  8
• 包装等级：
  II
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H314
• 储存条件：
  | 2～8℃ |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Dimethyl fluoromalonate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H314: Causes severe skin burns and eye damage
H318: Causes serious eye damage
P260: Do not breathe dust/fume/gas/mist/vapours/spray
P303+P361+P353: IF ON SKIN (or hair): Remove/Take off immediately all contaminated clothing. Rinse skin with
water/shower
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P301+P330+P331: IF SWALLOWED: Rinse mouth. Do NOT induce vomiting
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: Dimethyl fluoromalonate
CAS number: 344-14-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H7FO4
Molecular weight: 150.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN3261 Class: 8 Packing group: II
Proper shipping name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S. (Dimethyl fluoromalonate)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

2-氟丙二酸二甲酯用作有机合成中的重要中间体。

反应信息

• 作为反应物：
  描述：

  2-氟丙二酸二甲酯 在 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 1.5h， 生成 2-fluoro-3-methoxy-3-oxopropanoic acid
  参考文献：
  名称：

  相转移催化去对称化高对映选择性合成α,α-二烷基丙二酸酯

  摘要：

  开发了一种新型的对映选择性合成方法，用于通过相转移催化 (PTC) 烷基化从丙二酸酯构建季碳中心。在 (S,S)-3,4,5- 存在下，在相转移催化条件（50% KOH 水溶液，甲苯，0°C）下，α-烷基丙二酸二苯基甲基叔丁基酯与烷基化剂的不对称 α-烷基化三氟苯基-NAS溴化物（8）作为PTC催化剂以高化学（高达99％）和光学产率（高达97％ee）提供相应的α，α-二烷基丙二酸酯，可以很容易地转化为多功能手性中间体。值得注意的是，二苯基甲基叔丁基丙二酸酯的直接双α-烷基化也提供了相应的α,α-二烷基丙二酸酯，而不会损失对映选择性。该方法的合成潜力已通过α的制备得到证明，

  DOI：

  10.1021/ja110349a
• 作为产物：
  描述：

  丙二酸二甲酯 在 铀(VI)氟化物 作用下， 以 1,1,2-三氯三氟乙烷（CFC-113） 为溶剂， 反应 20.0h， 以15%的产率得到2-氟丙二酸二甲酯
  参考文献：
  名称：

  （再）研究六氟化铀在室温下对几种有机功能的反应性

  摘要：

  全球每年生产UF的6是非常大的，而不是使用这种化合物。因此，它可能是有趣的发现一些应用有机试剂。UF 6可以被认为是各种功能的氧化剂。但是，在温和的条件下作为氟化试剂似乎也存在一些可能性。

  DOI：

  10.1016/j.jfluchem.2014.06.007
• 作为试剂：
  描述：

  (E)-3-{4-[(R)-2-(1H-indol-3-ylmethyl)-pyrrolidin-1-ylmethyl]-phenyl}-acrylic acid methyl ester 在 2-氟丙二酸二甲酯 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 以28.6%的产率得到(Z)-2-fluoro-3-{4-[(R)-2-(1H-indol-3-ylmethyl)-pyrrolidin-1-ylmethyl]-phenyl}-acrylic acid methyl ester
  参考文献：
  名称：

  Hydroxamate-Based Inhibitors of Deacetylases

  摘要：

  本教导涉及Formula I的化合物：及其药用盐、水合物、酯和前药，其中R1、R2、R3、R4、R5、环A和Z的定义如本文所述。本教导还提供制备Formula I化合物的方法，以及利用Formula I化合物治疗完全或部分由去乙酰酶介导的病理状况或疾病的方法。

  公开号：

  US20110060009A1

文献信息

• [EN] HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS<br/>[FR] COMPOSÉS D'AMINOPYRIDINE SUBSTITUÉS PAR HÉTÉROARYLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2016210034A1

  公开（公告）日：2016-12-29

  Disclosed are compounds of Formula (I) or salts thereof, wherein HET is a heteroaryl selected from pyrrolo[2,3 b]pyridinyl, pyrrolo[2,3 d]pyrimidinyl, pyrazolo[3,4 b]pyridinyl, pyrazolo[3,4 d]pyrimidinyl, imidazolo[4,5 b]pyridinyl, and imidazolo[4,5 d]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a nitrogen ring atom in said heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; A is pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxadiazolyl or dihydroisoxazolyl, each substituted with zero or 1 Ra; and R3, Ra, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

  公开的是Formula (I)的化合物或其盐，其中HET是从吡咯并[2,3 b]吡啶基、吡咯并[2,3 d]嘧啶基、吡唑并[3,4 b]吡啶基、吡唑并[3,4 d]嘧啶基、咪唑并[4,5 b]吡啶基和咪唑并[4,5 d]嘧啶基中选择的杂芳基，其中所述杂芳基通过所述杂芳基中的一个氮环原子连接到Formula (I)的化合物中的吡啶基，并且所述杂芳基被取代为零至2个Rb；A是吡唑基、咪唑基、三唑基、异噁唑基、噁二唑基或二氢异噁唑基，每个取代为零或1个Ra；R3、Ra和Rb在此处定义。还公开了使用这些化合物作为IRAK4调节剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓炎症和自身免疫疾病，或在癌症治疗中是有用的。
• Design and Synthesis of 2,3-<i>trans</i>-Proline Analogues as Ligands for Ionotropic Glutamate Receptors and Excitatory Amino Acid Transporters
  作者：Christian B. M. Poulie、Anna Alcaide、Mikkel Krell-Jørgensen、Younes Larsen、Eloi Astier、Walden E. Bjørn-Yoshimoto、Feng Yi、Jed T. Syrenne、Morten Storgaard、Birgitte Nielsen、Karla A. Frydenvang、Anders A. Jensen、Kasper B. Hansen、Darryl S. Pickering、Lennart Bunch

  DOI：10.1021/acschemneuro.9b00205

  日期：2019.6.19

  developed for the efficient synthesis of racemic 3a and applied to give expedited access to 13 racemic analogues of 3a. Pharmacological characterization was carried out at native iGluRs, cloned homomeric kainate receptors (GluK1-3), NMDA receptors (GluN1/GluN2A-D), and excitatory amino acid transporters (EAAT1-3). From the structure-activity relationship studies, several new ligands emerged, exemplified by

  离子型谷氨酸受体（iGluRs）药理学工具的开发对于研究和了解这些受体在中枢神经系统中的作用和功能至关重要。我们报告了（2 S，3 R）-2-羧基-3-吡咯烷乙酸（3a）的18个类似物的合成，探讨了在ε-碳（3c-q）上引入取代基的作用。为有效合成外消旋体3a而开发了一种新的合成方法，并将其应用于加快获得13a 3a外消旋体类似物的途径。在天然iGluRs，克隆的同质红藻氨酸受体（GluK1-3），NMDA受体（GluN1 / GluN2A-D）和兴奋性氨基酸转运蛋白（EAAT1-3）上进行了药理学表征。从结构活性关系研究中，出现了几个新的配体，例如三唑3p-d1，
• [EN] PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES<br/>[FR] PRÉPARATION ET UTILISATIONS DE DÉRIVÉS DE PYRIMIDINONE
  申请人：CANCER RESEARCH TECH LTD

  公开号：WO2018055402A1

  公开（公告）日：2018-03-29

  The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, and n are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

  本发明涉及式(I)的化合物，以及其盐和溶剂合物，其作为细胞分裂周期7（Cdc7）激酶酶活性的抑制剂：（式(I)）其中X，R1，R2和n如本文所定义。本发明还涉及制备这些化合物的方法，包括它们的药物组合物，以及它们在治疗增殖性疾病（如癌症）以及其他涉及Cdc7激酶活性的疾病或病况中的用途。
• Phosphine-Mediated MBH-Type/Umpolung Addition Domino Sequence: Divergent Construction of Coumarins
  作者：Zhi-Xiong Deng、Yu Zheng、Zhen-Zhen Xie、Yue-Heng Gao、Jun-An Xiao、Si-Qi Xie、Hao-Yue Xiang、Xiao-Qing Chen、Hua Yang

  DOI：10.1021/acs.orglett.9b04248

  日期：2020.1.17

  We herein report a phosphine-mediated domino process of MBH-type reaction/umpolung γ-addition through the rational integration of the privileged reactivities of alkynoate. Simply by manipulating the nucleophilic reagent, the developed protocol offers a facile, diversity-oriented construction of a wide range of three-substituted coumarins.

  我们在这里报告了通过膦酸酯介导的特权反应性的合理整合，进行了膦介导的MBH型反应/蛋白γ加成的多米诺过程。只需通过操作亲核试剂，开发的方案即可轻松实现面向多样性的多种三取代香豆素的构建。
• INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
  申请人：Shire Human Genetic Therapies, Inc.

  公开号：US20190284182A1

  公开（公告）日：2019-09-19

  The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

  本发明提供了作为血浆激肽酶抑制剂并具有相同理想特性的化合物和组合物。